Dermatology

Review of Systemic Treatment of Psoriasis Recommends Biologics

November 25th 2017

By Jackie Syrop

Article

A new review discusses the systemic treatment of psoriasis and recommends biologics and biosimilars for long-term treatment of psoriasis because of their better tolerability and safety compared with other systemic treatments, which are limited largely by poor tolerability and cumulative toxicity.

NHS: Biologics Benefit Children With Plaque Psoriasis, But Cost-Effectiveness Uncertain

November 20th 2017

By Jackie Syrop

Article

A recent Health Technology Assessment (HTA) report by the United Kingdom’s National Institute for Health and Care Excellence (NICE) concludes that adalimumab, etanercept, and ustekinumab improve the symptoms of psoriasis in children and young people in the short term, but the cost-effectiveness of these medications requires further study.

UK Health Professionals Are Well Informed About Biosimilars

July 6th 2017

By Jackie Syrop

Article

A survey and drug utilization analysis conducted among UK healthcare professionals found that 75% of respondents were aware that biosimilars were available on their local formularies, and 77% considered biosimilars to be either extremely or very important to save costs for the National Health Service.